These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36135712)

  • 1. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
    Goel S; Tan AR; Rugo HS; Aftimos P; Andrić Z; Beelen A; Zhang J; Yi JS; Malik R; O'Shaughnessy J
    Future Oncol; 2022 Oct; 18(33):3701-3711. PubMed ID: 36135712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
    Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.
    Tan AR; O'Shaughnessy J; Cao S; Ahn S; Yi JS
    Breast Cancer Res Treat; 2023 Sep; 201(2):307-316. PubMed ID: 37418031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.
    Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Xiao J; Sorrentino J; Horton J; O'Shaughnessy J
    Clin Cancer Res; 2022 Feb; 28(4):629-636. PubMed ID: 34887261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
    Weiss JM; Csoszi T; Maglakelidze M; Hoyer RJ; Beck JT; Domine Gomez M; Lowczak A; Aljumaily R; Rocha Lima CM; Boccia RV; Hanna W; Nikolinakos P; Chiu VK; Owonikoko TK; Schuster SR; Hussein MA; Richards DA; Sawrycki P; Bulat I; Hamm JT; Hart LL; Adler S; Antal JM; Lai AY; Sorrentino JA; Yang Z; Malik RK; Morris SR; Roberts PJ; Dragnev KH;
    Ann Oncol; 2019 Oct; 30(10):1613-1621. PubMed ID: 31504118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
    Cortés J; André F; Gonçalves A; Kümmel S; Martín M; Schmid P; Schuetz F; Swain SM; Easton V; Pollex E; Deurloo R; Dent R
    Future Oncol; 2019 Jun; 15(17):1951-1961. PubMed ID: 30977385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
    Diéras V; Bonnefoi H; Alba E; Awada A; Coudert B; Pivot X; Gligorov J; Jager A; Zambelli S; Lindeman GJ; Charpentier E; Emmons GT; Garcia-Ribas I; Paridaens R; Verweij J
    Breast Cancer Res Treat; 2019 Sep; 177(2):383-393. PubMed ID: 31172407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
    Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
    Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
    Yardley DA; Ward PJ; Daniel BR; Eakle JF; Lamar RE; Lane CM; Hainsworth JD
    Clin Breast Cancer; 2016 Oct; 16(5):349-355. PubMed ID: 27340049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
    Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
    Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
    O'Shaughnessy J; Schwartzberg L; Danso MA; Miller KD; Rugo HS; Neubauer M; Robert N; Hellerstedt B; Saleh M; Richards P; Specht JM; Yardley DA; Carlson RW; Finn RS; Charpentier E; Garcia-Ribas I; Winer EP
    J Clin Oncol; 2014 Dec; 32(34):3840-7. PubMed ID: 25349301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
    Cheng Y; Wu L; Huang D; Wang Q; Fan Y; Zhang X; Fan H; Yao W; Liu B; Yu G; Pan Y; Xu F; He Z; Dong X; Ma R; Min X; Ge X; Chen H; Liu Q; Hu Y; Liu Y; Yang C; Yang Y; Li X; Zhou L
    Lung Cancer; 2024 Feb; 188():107455. PubMed ID: 38224653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
    BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
    Yardley DA; Coleman R; Conte P; Cortes J; Brufsky A; Shtivelband M; Young R; Bengala C; Ali H; Eakel J; Schneeweiss A; de la Cruz-Merino L; Wilks S; O'Shaughnessy J; Glück S; Li H; Miller J; Barton D; Harbeck N;
    Ann Oncol; 2018 Aug; 29(8):1763-1770. PubMed ID: 29878040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
    Slater H
    Oncology (Williston Park); 2020 Dec; 34(12):547. PubMed ID: 33395495
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
    Cowherd S; Miller LD; Melin SA; Akman S; Isom S; Cole J; Pullikuth A; Lawrence JA
    Cancer Biol Ther; 2015; 16(5):678-83. PubMed ID: 25928118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.